Adrenocortical Carcinoma Market Size was valued USD 30 million in 2024 and is Expected to grow by 2034

The Adrenocortical Carcinoma market across the 7MM was valued at around USD 30 million in 2024 and is anticipated to experience significant growth over the forecast period, driven by the potential introduction of innovative therapies such as CY-101 from Cytovation and OR-449 from Orphagen Pharmaceuticals. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Adrenocortical Carcinoma landscape.

According to DelveInsight’s 2024 analysis, there were around 1,250 new cases of Adrenocortical Carcinoma in the 7MM. These cases are expected to rise at a notable CAGR over the forecast period from 2025 to 2034. In 2023, incident cases of Adrenocortical Carcinoma in the 7MM were divided into four age groups: <20 years, 20–40 years, 41–60 years, and >60 years. The highest number of cases was observed in the 41–60 years group, followed by >60 years, 20–40 years, and <20 years.

In the 7MM, the stage-wise distribution of Adrenocortical Carcinoma shows that Stage IV accounts for the largest share at 35%, followed by Stage II at 30%, Stage III at 24%, and Stage I at 11%. The high proportion of Stage IV cases may be due to delayed diagnosis, aggressive disease progression, and limited screening methods, emphasizing the need for enhanced detection strategies. In 2024, 40% of cases occurred in males and 60% in females across the seven major markets.

DelveInsight’s report “Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Adrenocortical Carcinoma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

To Know in detail about the Adrenocortical Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenocortical Carcinoma Market Forecast

Some of the key facts of the Adrenocortical Carcinoma Market Report:

• Key Adrenocortical Carcinoma Companies: Orphagen Pharmaceuticals, Corcept Therapeutics, Cytovation, Merck, Enterome/Bristol-Myers Squibb, UNICANCER, Fusion Pharmaceuticals, and others
• Key Adrenocortical Carcinoma Therapies: OR-449, Relacorilant, CY-101, Pembrolizumab, EO2401 + Nivolumab, Dostarlimab, [111In]-FPI-1547 Injection, and others
• The Adrenocortical Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adrenocortical Carcinoma pipeline products will significantly revolutionize the Adrenocortical Carcinoma market dynamics.

Adrenocortical Carcinoma Overview

Adrenocortical Carcinoma is a rare and aggressive cancer originating in the cortex (outer layer) of the adrenal glands, which are located above the kidneys and produce hormones like cortisol, aldosterone, and androgens. ACC can cause hormone overproduction, leading to symptoms such as weight gain, high blood pressure, excessive hair growth, or changes in metabolism. The disease is often diagnosed at an advanced stage due to nonspecific symptoms. Treatment typically involves surgery, and in some cases, chemotherapy, targeted therapy, or hormone-blocking medications to manage tumor growth and hormone-related effects.

Get a Free sample for the Adrenocortical Carcinoma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/adrenocortical-carcinoma-market

Key Trends in Adrenocortical Carcinoma Therapeutics Market:

• Emergence of Targeted Therapies: Increasing development of molecularly targeted agents, including IGF-1R inhibitors and tyrosine kinase inhibitors.
• Focus on Immunotherapy: Growing exploration of checkpoint inhibitors and other immunotherapies to improve patient survival.
• Personalized and Precision Medicine Approaches: Expansion of genomic profiling to tailor treatments based on tumor mutations.
• Combination Treatment Strategies: Integration of surgery, mitotane therapy, and systemic therapies for enhanced treatment outcomes.
• Rising Clinical Research and Trials: Increasing global clinical trials investigating novel agents and therapeutic regimens for Adrenocortical Carcinoma.

Adrenocortical Carcinoma Epidemiology

The Adrenocortical Carcinoma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Adrenocortical Carcinoma Epidemiology Segmentation:

The Adrenocortical Carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Incident Cases of Adrenocortical Carcinoma in the 7MM
• Stage-specific Incident Cases of Adrenocortical Carcinoma in the 7MM
• Gender-specific Incident Cases of Adrenocortical Carcinoma in the 7MM
• Age-specific Incident Cases of Adrenocortical Carcinoma in the 7MM

Download the report to understand which factors are driving Adrenocortical Carcinoma epidemiology trends @ Adrenocortical Carcinoma Epidemiology Forecast

Recent Developments In The Adrenocortical Carcinoma Treatment Landscape:

• In April 2025, Cytovation ASA, a clinical-stage oncology company developing its first-in-class bifunctional peptide CY-101, announced it has secured NOK 62 million (USD 6 million), primarily from existing investors and led by Sandwater, to support the Phase II development of CY-101 in adrenocortical carcinoma toward initial clinical readouts.
• In November 2024, The Cancer Prevention & Research Institute of Texas (CPRIT) announced plans to grant Orphagen USD 10.2 million over three years to partially support the final stages of IND filing and a Phase I clinical trial for OR-449, a novel orally bioavailable small-molecule therapeutic candidate targeting adrenocortical cancer (ACC).

Adrenocortical Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenocortical Carcinoma market or expected to get launched during the study period. The analysis covers Adrenocortical Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Adrenocortical Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Adrenocortical Carcinoma Therapies and Key Companies

• OR-449: Orphagen Pharmaceuticals
• Relacorilant: Corcept Therapeutics
• CY-101: Cytovation
• Pembrolizumab: Merck
• EO2401 + Nivolumab : Enterome/Bristol-Myers Squibb
• Dostarlimab: UNICANCER
• [111In]-FPI-1547 Injection: Fusion Pharmaceuticals

Discover more about therapies set to grab major Adrenocortical Carcinoma market share @ Adrenocortical Carcinoma Treatment Landscape

Adrenocortical Carcinoma Market Drivers

• Rising Incidence of Adrenocortical Carcinoma: Although rare, increasing diagnosis rates due to advanced imaging and awareness contribute to market growth.
• Advancements in Targeted Therapies: Development of molecularly targeted agents, such as IGF-1R inhibitors and tyrosine kinase inhibitors, improves treatment outcomes.
• Growth in Immunotherapy Research: Exploration of checkpoint inhibitors and other immunotherapies offers new treatment avenues.
• Expansion of Precision Medicine: Genomic profiling enables personalized treatment strategies for better efficacy.
• Increasing Clinical Trials and R&D Investments: Pharma and biotech companies are actively researching novel therapies for Adrenocortical Carcinoma.

Adrenocortical Carcinoma Market Barriers

• Rarity of the Disease: Low patient population limits large-scale clinical studies and commercial interest.
• Poor Prognosis and Aggressive Nature: Short survival rates reduce long-term treatment adoption.
• Limited Effective Treatment Options: Existing therapies often have low efficacy and high toxicity.
• High Treatment Costs: Advanced therapies, including targeted agents and immunotherapies, are expensive.
• Regulatory and Reimbursement Challenges: Stringent approval processes and limited insurance coverage can hinder market growth.

Scope of the Adrenocortical Carcinoma Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Adrenocortical Carcinoma Companies: Orphagen Pharmaceuticals, Corcept Therapeutics, Cytovation, Merck, Enterome/Bristol-Myers Squibb, UNICANCER, Fusion Pharmaceuticals, and others
• Key Adrenocortical Carcinoma Therapies: OR-449, Relacorilant, CY-101, Pembrolizumab, EO2401 + Nivolumab, Dostarlimab, [111In]-FPI-1547 Injection, and others
• Adrenocortical Carcinoma Therapeutic Assessment: Adrenocortical Carcinoma current marketed and Adrenocortical Carcinoma emerging therapies
• Adrenocortical Carcinoma Market Dynamics: Adrenocortical Carcinoma market drivers and Adrenocortical Carcinoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Adrenocortical Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Adrenocortical Carcinoma Market Access and Reimbursement

To know more about Adrenocortical Carcinoma companies working in the treatment market, visit @ Adrenocortical Carcinoma Clinical Trials and Therapeutic Assessment